CN112010971A - Application of anti-VEGF antibody in preparation of medicine for preventing and/or treating fatty liver - Google Patents
Application of anti-VEGF antibody in preparation of medicine for preventing and/or treating fatty liver Download PDFInfo
- Publication number
- CN112010971A CN112010971A CN201910462779.1A CN201910462779A CN112010971A CN 112010971 A CN112010971 A CN 112010971A CN 201910462779 A CN201910462779 A CN 201910462779A CN 112010971 A CN112010971 A CN 112010971A
- Authority
- CN
- China
- Prior art keywords
- fatty liver
- vegf antibody
- preventing
- medicament
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
The invention provides an application of an anti-VEGF antibody in preparing a medicament for preventing and/or treating fatty liver, and provides a new application of the anti-VEGF antibody. The invention also provides a medicament for preventing and/or treating fatty liver.
Description
Technical Field
The invention relates to the technical field of medical drugs, in particular to application of an anti-VEGF antibody in preparing a drug for preventing and/or treating fatty liver.
Background
Fatty Liver (FLD), also known as hepatocellular steatosis, is a disease in which excess fat is deposited in the liver, and is classified into non-alcoholic Fatty liver disease and alcoholic liver disease. Non-alcoholic steatohepatitis consists of simple fatty liver and non-alcoholic steatohepatitis, and the main risk factors of the non-alcoholic steatohepatitis include fatty liver, obesity, advanced age and the like. The prevalence rates of the general population in different countries are between 10% and 24%. Non-alcoholic fatty liver disease is observed in up to 80% of obese people. Fatty liver can develop into fibrosis or liver cancer. These pathologies are closely related to metabolic diseases (e.g. type II fatty liver, metabolic syndrome) which also affect non-obese people. The treatment of fatty liver depends on its causes, and two known causes are excessive drinking and long-term eating, drugs that reduce insulin resistance, hyperlipidemia, and drugs that induce weight loss, have been shown to improve or resolve liver functions.
Disclosure of Invention
In order to solve the problems, the invention provides a new application of an anti-VEGF antibody, namely an application of the anti-VEGF antibody in preparing a medicament for preventing and/or treating fatty liver, wherein the anti-VEGF antibody can reduce the blood sugar content, increase the insulin sensitivity, reduce the size of a hepatic cell lipid droplet and relieve the fatty liver, and the anti-VEGF antibody can be applied to the medicament to achieve the purpose of preventing and/or treating the fatty liver.
In a first aspect, the invention provides the use of an anti-VEGF antibody in the manufacture of a medicament for the prevention and/or treatment of fatty liver.
In the invention, the anti-VEGF antibody is already applied to treatment of metastatic rectal cancer, ophthalmic diseases and the like, and the application of the anti-VEGF antibody in prevention and/or treatment of fatty liver is not reported, so that the applicant finds through experiments that the anti-VEGF antibody can reduce the blood sugar content, increase the insulin sensitivity, reduce the size of fat droplets in liver cells and relieve the fatty liver, can be applied to medicaments for preventing and/or treating the fatty liver, and provides a new idea for treatment of the fatty liver.
Optionally, the anti-VEGF antibody inhibits hepatic blood vessels, reduces liver weight, and lipids in hepatocytes.
Optionally, the content of the anti-VEGF antibody in the drug for preventing and/or treating fatty liver is more than 10%. Further, the content of the anti-VEGF antibody in the drug for preventing and/or treating fatty liver is more than 15%.
Optionally, the anti-VEGF antibody comprises at least one of bevacizumab, aflibercept, ramucirumab and ranibizumab.
In the present invention, the anti-VEGF antibody is a monoclonal antibody.
Optionally, the anti-VEGF antibody is a humanized antibody.
Optionally, the anti-VEGF antibody as a single active ingredient or with other pharmaceutically acceptable active ingredients constitutes the medicament for preventing and/or treating fatty liver.
In the invention, the anti-VEGF antibody can be used as a sole active ingredient to prepare a medicament for preventing and/or treating fatty liver, and can also be used for preparing a medicament for preventing and/or treating fatty liver together with other pharmaceutically acceptable active ingredients. The other pharmaceutically acceptable active ingredients may be active ingredients for preventing and/or treating fatty liver, or active ingredients for preventing and/or treating other diseases, which is not limited herein.
Further, the other pharmaceutically acceptable active ingredients include one or more of insulin sensitizers, tiopronin, apomosis, and rizarone.
In the present invention, the other pharmaceutically acceptable active ingredient has an effect of preventing and/or treating fatty liver.
Optionally, the mass ratio of the anti-VEGF antibody to the other pharmaceutically acceptable active ingredients is 1: (0.1-0.8). Further, the mass ratio of the anti-VEGF antibody to the other pharmaceutically acceptable active ingredients is 1: (0.2-0.7).
In the invention, the anti-VEGF antibody can act together with other pharmaceutically acceptable active ingredients to achieve the aim of preventing and/or treating fatty liver.
Optionally, the medicament for preventing and/or treating fatty liver further comprises a pharmaceutically acceptable carrier and/or an auxiliary material.
Optionally, the carrier includes one or more of a solvent, a polymer, and a liposome, but is not limited thereto. Further, the solvent includes, but is not limited to, water, physiological saline, and other non-aqueous solvents. Further, the polymer includes one or more of polylysine, polyethyleneimine (branched and/or chain) and its modified substance, polyamidoamine dendrimer (PAMAM) and its derivative, polypropyleneimine dendrimer (PPI) and its derivative, chitosan, polylactic-co-glycolic acid (PLGA), polylactic acid, gelatin, cyclodextrin, sodium alginate, albumin, and hemoglobin, but is not limited thereto. Further, the liposome can be self-assembled from cationic lipid, neutral auxiliary lipid, cholesterol, and phospholipid (such as soybean lecithin, egg yolk lecithin, cephalin, etc.), or can be formed by inserting distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG) into phospholipid layer formed by phospholipid molecules.
In the present invention, the anti-VEGF antibody may be dispersed or adsorbed in the above-mentioned carrier to form a dispersion system, or may be encapsulated by the above-mentioned liposome or polymer to form a spherical structure (e.g., nanocapsule or microcapsule). The anti-VEGF antibody encapsulated in the spherical structure can perform sustained release, controlled release or targeted release, so that the drug can exert the optimal efficacy, the stability of the drug can be improved, and the stimulation of the drug can be reduced. For example, albumin, gelatin, chitosan, polylactic acid can generally form microspheres that can disperse or encapsulate a drug.
In the present invention, the "pharmaceutically acceptable carrier" is used to transport the drug of the present invention to exert its intended effect. In general, delivery is from one organ or portion to another, and the carrier must be compatible with the pharmaceutical composition, not interfere with the biological activity of the drug, and be relatively non-toxic, e.g., the carrier enters the body without causing toxic side effects or having a severe reaction with the drug it carries, which does not adversely affect the patient.
Optionally, the excipient comprises one or more of a diluent, an excipient and a stabilizer.
In the present invention, the diluent mainly functions to fill the weight or volume of the tablet to facilitate tableting. Further, the diluent includes one or more of starches, sugars, celluloses and inorganic salts. In the present invention, the excipient means an additive in the drug in addition to the main pharmaceutically active ingredient. Further, the excipient includes, for example, a binder, a filler, a disintegrating agent, a lubricant in a tablet, a wine, a vinegar, a medical juice in a pill, etc., a base part in a semisolid preparation ointment, a cream, a flavoring agent, an aromatic, a solubilizing agent, an emulsifying agent, a solubilizing agent, an osmotic pressure regulator, a coloring agent, etc. in a liquid preparation. In the present invention, the stabilizer mainly functions to stabilize each component in the drug, and the stabilizer may be, but not limited to, a preservative, an antioxidant, a cosolvent, an emulsifier, a solubilizer, and the like.
Optionally, the medicament for preventing and/or treating fatty liver comprises one or more of decoction, powder, tablets, capsules, pills, oral preparations and granules. The form of the agent for preventing and/or treating fatty liver depends on the actual use.
Optionally, the fatty liver comprises one or more of fatty liver with obesity, alcoholic fatty liver, non-alcoholic fatty liver, fatty liver with rapid obesity, fatty liver with malnutrition, fatty liver with diabetes and fatty liver with medicine. In particular, but not limited to, the anti-VEGF antibody can be applied to the preparation of medicines for preventing and/or treating non-alcoholic fatty liver disease.
Alternatively, the medicament for preventing and/or treating fatty liver is administered orally or by injection.
Alternatively, the injection is administered by intraperitoneal injection, subcutaneous injection, intramuscular injection or intravenous injection.
Optionally, the anti-VEGF antibody is administered at a daily dose of (2.5-30) mg/kg body weight. Further, the anti-VEGF antibody is administered at a daily dose of (5-25) mg/kg body weight. Further, the anti-VEGF antibody is administered at a daily dose of (5-20) mg/kg body weight.
The invention provides a new application of an anti-VEGF antibody, wherein the anti-VEGF antibody is used for preparing a medicament for preventing and/or treating fatty liver, can reduce the blood sugar content, increase the insulin sensitivity, reduce the size of a hepatic cell lipid drop and relieve the fatty liver, and the anti-VEGF antibody is applied to the medicament to achieve the purpose of preventing and/or treating the fatty liver.
In a second aspect, the present invention provides a medicament for preventing and/or treating fatty liver, comprising an anti-VEGF antibody.
In the invention, the anti-VEGF antibody can reduce the blood sugar content, increase the insulin sensitivity, reduce the size of a hepatic cell lipid drop and relieve fatty liver, and can achieve the purpose of preventing and/or treating fatty liver by applying the anti-VEGF antibody to a medicament.
Optionally, the amount of the anti-VEGF antibody in the medicament is greater than 10%. Further, the amount of the anti-VEGF antibody in the medicament is greater than 15%.
Optionally, the anti-VEGF antibody as a single active ingredient or with other pharmaceutically acceptable active ingredients constitutes the medicament for preventing and/or treating fatty liver. Further, the other pharmaceutically acceptable active ingredients include one or more of insulin sensitizers, tiopronin, apomosis, and rizarone.
Optionally, the medicament for preventing and/or treating fatty liver further comprises a pharmaceutically acceptable carrier and/or an auxiliary material. Further, the carrier includes one or more of a solvent, a polymer, and a liposome. Further, the auxiliary materials comprise one or more of diluents, excipients and stabilizers.
Optionally, the medicament for preventing and/or treating fatty liver comprises one or more of decoction, powder, tablets, capsules, pills, oral preparations and granules.
Alternatively, the medicament for preventing and/or treating fatty liver is administered orally or by injection.
The invention provides a medicament for preventing and/or treating fatty liver, which comprises an anti-VEGF antibody. The anti-VEGF antibody can reduce the blood sugar content, increase the insulin sensitivity, reduce the size of fat drops of liver cells and relieve fatty liver, and can achieve the purpose of preventing and/or treating fatty liver by applying the anti-VEGF antibody to a medicament.
Advantages of embodiments of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of embodiments of the invention.
Drawings
FIG. 1 is a graph showing results of body weight and BMI in mice, wherein (a) in FIG. 1 is a graph showing body weight comparison and (b) in FIG. 1 is a graph showing BMI comparison;
FIG. 2 is a graph of results of glucose tolerance and insulin tolerance in mice; wherein (a) in fig. 2 is a graph of the percentage of blood glucose in a glucose tolerance test, fig. 2 (b) is a graph of the area of a curve in a glucose tolerance test, fig. 2 (c) is a graph of the percentage of blood glucose in an insulin tolerance test, fig. 2 (d) is a graph of the area of a curve in an insulin tolerance test, and fig. 2 (e) is a graph of the fasting blood glucose content;
fig. 3 is a diagram showing the appearance and histological examination of the liver of a mouse, wherein (a) in fig. 3 is a diagram showing the morphology of the liver tissue and HE staining, and (b) in fig. 3 is a diagram showing the comparison of the weight of the liver.
Detailed Description
While the following is a description of the preferred embodiments of the present invention, it should be noted that those skilled in the art can make various modifications and improvements without departing from the principle of the embodiments of the present invention, and such modifications and improvements are considered to be within the scope of the embodiments of the present invention.
Example 1:
in the animal experiment, male C57Bl/6 mice of 6 to 8 weeks old were used, and the mice were maintained under standard animal feeding conditions, and in a fatty liver mouse model, liver steatosis was induced using a high-fat diet for 3 months or more, and normal mice were fed with a standard diet.
Experimental groups: 5mg/kg of a rabbit anti-mouse monoclonal VEGF-specific neutralizing antibody (cat # BD0801, supplied by Xiansu pharmaceutical company (Nanjing, Jiangsu, China) was intraperitoneally injected 2 times a week into fatty liver mice.
Control group 1: normal mice were injected with non-immune rabbit IgG antibodies, and the rest were identical to the experimental group method.
Control group 2: injecting rabbit anti-mouse monoclonal VEGF specific neutralizing antibody to normal mouse, and the rest is identical to the experimental group method.
Control group 3: the fatty liver mice were injected with non-immune rabbit IgG antibodies, and the rest were identical to the experimental group methods.
Changes in body weight and Body Mass Index (BMI) were measured in each group of mice and the results are shown in FIG. 1. It can be seen that treatment with anti-VEGF antibody did not affect body weight and BMI in normal mice as well as in fatty liver mice.
A glucometer and a matching blood glucose test strip were used to measure fasting glucose and to monitor blood glucose levels. Fasting was 6 hours before fasting and fasting blood glucose levels were measured in each group of mice using blood glucose strips. For the glucose tolerance test, all mice were fasted for 6 hours and were injected intraperitoneally with 1g/kg glucose. Blood glucose levels were monitored at 0, 15, 30, 60, 90 and 120 minutes post injection. For insulin resistance experiments, all mice were fasted for 6 hours prior to the experiment and then injected i.p. with 0.5U/kg human insulin. Blood glucose was monitored by tail vein bleeds at 0, 15, 30, 60, 90 and 120 minutes post injection, and the results are shown in figure 2. The anti-VEGF antibody can reduce fasting plasma glucose of a normal mouse, but does not influence insulin sensitivity of the normal mouse, which shows that the anti-VEGF antibody treatment has no obvious effect on the normal mouse; anti-VEGF antibodies can reduce fasting plasma glucose in fatty liver mice, while also increasing insulin sensitivity in fatty liver mice.
After 4 weeks, each group of mice was examined histologically, and the results are shown in fig. 3. It can be seen that there was no significant difference in liver cell morphology and no significant change in weight for each group of mice. It can be seen by HE staining that the liver of the control group 3 mice has obvious lipid droplet vacuole and surface lipoid change, and after the experimental group mice are injected with the anti-VEGF antibody 2 times a week for 14 days and 28 days, the lipid droplet vacuole phenomenon is obviously improved, and has no obvious difference with the staining forms of the control group 1 and the control group 2.
In conclusion, compared with the control group 1 mice, the liver morphology and histology of the mice in the control group 2 were not significantly changed, and the anti-VEGF antibody treatment could reduce fasting plasma glucose without affecting insulin sensitivity, indicating that the anti-VEGF antibody treatment had no significant effect on normal mice. Compared with the control group 1 and the control group 3, the liver morphology and the histology of the mice in the experimental group are improved, the oral glucose tolerance experiment and the insulin tolerance experiment are also improved, which shows that the anti-VEGF antibody can improve the fatty liver, and the anti-VEGF antibody can be used for preparing the medicine for preventing and/or treating the fatty liver, so that the purpose of preventing and/or treating the fatty liver is achieved.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. Application of anti-VEGF antibody in preparing medicine for preventing and/or treating fatty liver.
2. The use according to claim 1, wherein the amount of the anti-VEGF antibody in the medicament for the prevention and/or treatment of fatty liver is greater than 10%.
3. The use according to claim 1, wherein the anti-VEGF antibody constitutes the medicament for the prevention and/or treatment of fatty liver, as a single active ingredient or with other pharmaceutically acceptable active ingredients.
4. The use of claim 3, wherein the other pharmaceutically acceptable active ingredients comprise one or more of insulin sensitizers, tiopronin, apomosis and rizarone.
5. The use of claim 1, wherein said anti-VEGF antibody comprises at least one of bevacizumab, aflibercept, ramucirumab and ranibizumab.
6. The use of claim 1, wherein the medicament for preventing and/or treating fatty liver further comprises a pharmaceutically acceptable carrier and/or adjuvant.
7. The use of claim 6, wherein the carrier comprises one or more of a solvent, a polymer, and a liposome.
8. The use of claim 6, wherein the excipients comprise one or more of diluents, excipients and stabilizers.
9. The use of claim 1, wherein the fatty liver comprises one or more of obese fatty liver, alcoholic fatty liver, non-alcoholic fatty liver, rapidly-fatiguing fatty liver, dystrophic fatty liver, diabetic fatty liver, and medicated fatty liver.
10. A medicament for the prevention and/or treatment of fatty liver, comprising an anti-VEGF antibody.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910462779.1A CN112010971A (en) | 2019-05-30 | 2019-05-30 | Application of anti-VEGF antibody in preparation of medicine for preventing and/or treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910462779.1A CN112010971A (en) | 2019-05-30 | 2019-05-30 | Application of anti-VEGF antibody in preparation of medicine for preventing and/or treating fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112010971A true CN112010971A (en) | 2020-12-01 |
Family
ID=73501970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910462779.1A Pending CN112010971A (en) | 2019-05-30 | 2019-05-30 | Application of anti-VEGF antibody in preparation of medicine for preventing and/or treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112010971A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101204501A (en) * | 2006-12-21 | 2008-06-25 | 张介眉 | Application of anti-fatty liver Chinese traditional medicine and fistular onion stalk extractive on curing fatty liver |
| US20090010881A1 (en) * | 2003-05-30 | 2009-01-08 | Genentech, Inc. | Treatment with anti-vegf antibodies |
| CN103893759A (en) * | 2007-11-30 | 2014-07-02 | 基因技术公司 | Anti-VEGF antibodies |
| CN109310884A (en) * | 2016-04-21 | 2019-02-05 | Csl有限公司 | The method for treating or preventing hepatopathy |
-
2019
- 2019-05-30 CN CN201910462779.1A patent/CN112010971A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090010881A1 (en) * | 2003-05-30 | 2009-01-08 | Genentech, Inc. | Treatment with anti-vegf antibodies |
| CN101204501A (en) * | 2006-12-21 | 2008-06-25 | 张介眉 | Application of anti-fatty liver Chinese traditional medicine and fistular onion stalk extractive on curing fatty liver |
| CN103893759A (en) * | 2007-11-30 | 2014-07-02 | 基因技术公司 | Anti-VEGF antibodies |
| CN109310884A (en) * | 2016-04-21 | 2019-02-05 | Csl有限公司 | The method for treating or preventing hepatopathy |
Non-Patent Citations (3)
| Title |
|---|
| 李娟等: "中药复方降脂颗粒对高脂血症大鼠NO、VEGF的干预作用", 《新疆中医药》 * |
| 李娟等: "血管内皮生长因子与非酒精性脂肪性肝病", 《临床肝胆病杂志》 * |
| 欧阳小予等: "非酒精性脂肪性肝病患者血清VEGF水平与IL-6、hs-CRP的相关性分析", 《医学理论与实践》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108771657B (en) | Small molecule drug in-situ phase change gel sustained release system and preparation method thereof | |
| KR101068603B1 (en) | Formulations for treatment of adipose tissue, cutaneous tissue and disorders, and muscular tissue | |
| Gordon Still | Development of oral insulin: progress and current status | |
| Goktas et al. | Recent advances in nanoencapsulation of phytochemicals to combat obesity and its comorbidities | |
| HUE032368T2 (en) | Antisense compositions and methods of making and using same | |
| KR20090096756A (en) | A method of reducing serum proinsulin levels in type 2 diabetics | |
| WO2009012718A1 (en) | A composite emulsifier, an emulsion prepared from it and the preparation method thereof | |
| CN108495619A (en) | Echinomycin preparation and preparation method thereof and application method | |
| Wilson et al. | Recent advances in insulin therapy | |
| Demirtürk et al. | Nanocarriers targeting the diseases of the pancreas | |
| CN112010971A (en) | Application of anti-VEGF antibody in preparation of medicine for preventing and/or treating fatty liver | |
| US10342852B2 (en) | Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein | |
| CA2838739A1 (en) | Gel compositions | |
| CN104906114A (en) | Metformin-gliquidone compound sustained-release capsule and preparation method thereof | |
| CN105434336B (en) | Propranolol Hydrochloride external-use gel preparation and its preparation method and application | |
| Raj et al. | An overview of recent advances in insulin delivery and wearable technology for effective management of diabetes | |
| CN109893655B (en) | Application of miR-327 inhibitor and/or FGF10 promoter in medicine for preventing and/or treating diabetes | |
| CN106177962A (en) | Pharmaceutical composition containing Sarpogrelate is for treating or prevent the purposes of fatty liver, hepatic fibrosis and/or hepatic injury | |
| CN105381469A (en) | Medicine preparation for treating brain diseases | |
| Abderrahmani et al. | Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand? | |
| CN112007025B (en) | Application of mirabegron in preparation of medicine for preventing and/or treating malignant tumor | |
| US20220079975A1 (en) | Method for mitigation of non-alcoholic fatty liver disease by use of a composition comprising small-molecule fucoidan and fucoxanthin | |
| KR101719015B1 (en) | Pharmaceutical composition for preventing or treating obesity or metabolic disease comprising prunetin as an active ingredient | |
| CN103040751B (en) | Asarone lipidosome injection | |
| CN109893656B (en) | Application of miR-327 inhibitor and/or FGF10 promoter in preparation of medicines for preventing and/or treating lipodystrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201201 |
|
| RJ01 | Rejection of invention patent application after publication |